- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02872103
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, multi-center, single dose, double-blind, placebo controlled phase III study of the efficacy and safety of once-per-cycle of F-627 in women with stage II-IV breast cancer who are receiving myelotoxic TA chemotherapy treatment (Taxotere (docetaxel) + Adriamycin(doxorubicin)). F-627 is designed to treat neutropenia, an abnormally low number of neutrophils (a type of white blood cell) in the blood. Neutropenia is often seen in cancer patients receiving myelotoxic chemotherapy.
The primary objective of this study is to evaluate the efficacy and safety of single fixed dose of F-627 in breast cancer patients experiencing myelotoxic chemotherapy in comparison to placebo. F-627 or placebo is to be administered subcutaneously 24 hours after chemotherapy in each 21-day cycle of chemotherapy treatment (up to 4 cycles). Patients randomized to placebo arm will receive F-627 except in cycle 1. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC < 0.5 x 10^9/L) observed in chemotherapy cycle 1.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New Jersey
-
Princeton, New Jersey, United States, 08540
- Covance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
- Females ≥ 18 years of age and < 75 years of age.
- Diagnosed with Stage II-IV breast cancer.
- Subject is scheduled to undergo 4 cycles of TA chemotherapy (docetaxel, doxorubicin, 75, and 60 mg/m2, respectively).
- ECOG Performance status of ≤ 2.
- White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet count ≥ 150 × 109/L.
- Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
- All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.
Exclusion Criteria:
- Subject is <18 or ≥ 75 years of age.
- Disease progression has occurred while receiving a taxane regimen.
- Subject has undergone radiation therapy within 4 weeks of enrollment.
- Subject has undergone bone marrow or stem-cell transplantation.
- Subject has a history of prior malignancy other than breast cancer that is NOT in remission.
- Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e. lithium) within 6 weeks of the screening period are excluded.
- Subject has had chemotherapy within 365 days of screening.
- Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.
- History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
- Unwillingness to participate in the study.
- Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
- Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.
- Any condition, which can cause splenomegaly.
- Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
- ALT, AST, alkaline phosphatase, total bilirubin ≥ 2.5 upper limit of normal.
- Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
- Women who are pregnant or breast-feeding.
- Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
- Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
- Subjects with Sickle Cell disease
- Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: F-627
F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
|
F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles.
TA chemotherapy treatments are part of standard-of-care and not the study
|
Placebo Comparator: Placebo
Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
|
F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles.
TA chemotherapy treatments are part of standard-of-care and not the study
Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle.
TA chemotherapy treatments are part of standard-of-care and not the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo
Time Frame: The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks
|
Subjects will be randomized to F-627 or Placebo at 2:1 ratio.
About 24 hours after chemotherapy, subjects will either receive 20mg fixed dose F-627 or Placebo.
The subject's absolute neutrophil count (ANC) will be monitored each day post chemotherapy administration until the ANC level exceeds 2.0x10^9/L, then the value will be monitored every three days until the next chemotherapy cycle is entered.
The duration of grade 4 neutropenia (ANC <0.5x10^9/L) in this cycle is the primary efficacy endpoint.
|
The first of 4, 21 Day Chemotherapy Cycles, an average of 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Duration in Days of Grade 4 (Severe) Neutropenia (ANC < 0.5 × 10^9/L) for Chemotherapy Cycles 2, 3, and 4, and Over All Cycles.
Time Frame: Over all 4 cycles, about 12 weeks
|
The duration of severe neutropenia will be measured for each patient during chemotherapy cycle 2-4 and over all cycles.
Each chemotherapy is expected to last 21 days.
|
Over all 4 cycles, about 12 weeks
|
The Duration in Days of Grade 2 (Mild), Grade 3 (Moderate) and 4 (Severe) Neutropenia Over All Cycles.
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
The duration in days of mild, moderate and severe neutropenia will be recorded for 4 chemotherapy cycles.
Grade 2 neutropenia is when a patient's ANC<1.5x10^9/L,
Grade 3 neutropenia is when a patient's ANC<1.0x10^9/L, and Grade 4 neutropenia is when a patient's ANC <0.5x10^9/L.
|
4 chemotherapy cycles, about 12 weeks
|
Number of Participants With Febrile Neutropenia (FN) for Each Chemotherapy Cycle and Over All Cycles
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of >38.0°C (100.4°F)
sustained for >1 hour and ANC < 0.5 x 10^9/L
|
4 chemotherapy cycles, about 12 weeks
|
Number of Participants With Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles.
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
The number of subjects with grade 2, 3 and 4 neutropenia will be recorded for all 4 chemotherapy cycles.
|
4 chemotherapy cycles, about 12 weeks
|
The Time in Days to ANC Recovery Post Nadir for Each Chemotherapy Cycle and Over All Cycles; Recovery Defined as an ANC ≥ 2.0 × 10^9/L After the Expected ANC Nadir.
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded.
Recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration).
|
4 chemotherapy cycles, about 12 weeks
|
The Depth of the ANC Nadir for Each Chemotherapy Cycle and Over All Cycles.
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
The depth of ANC nadir for each cycle is the minimal ANC value (× 10^9/L ) for a patient in each chemotherapy cycle
|
4 chemotherapy cycles, about 12 weeks
|
Number of Participants With Infections for Each Chemotherapy Cycle and Over All Cycles.
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
The number of subjects with infections for each arm of the study will be recorded for each and all 4 chemotherapy cycles.
|
4 chemotherapy cycles, about 12 weeks
|
Number of Participants With Use of Antibiotics and Pain Medications
Time Frame: 4 chemotherapy cycles, about 12 weeks
|
Antibiotics and pain medications use will be recorded for each chemotherapy cycle and overall cycles
|
4 chemotherapy cycles, about 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kevin F Dreyer, EVIVE Biotechnology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GC-627-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on F-627
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingColorectal Cancer | Pancreatic CancerChina
-
EVIVE BiotechnologyCompletedBreast Cancer | NeutropeniaUnited States
-
EVIVE BiotechnologyCompleted
-
EVIVE BiotechnologyCompletedBreast Cancer | NeutropeniaUnited States
-
EVIVE BiotechnologySun Yat-sen University; Fudan UniversityCompleted
-
Aspen Medical ProductsTerminated
-
EVIVE BiotechnologyZhejiang Cancer Hospital; Fudan University; RenJi Hospital; Henan Cancer Hospital; Tongji Hospital and other collaboratorsCompleted
-
University of AlbertaSuspendedLow Back Pain | Magnetic Resonance Imaging | Bone Marrow Edema | Brace | Modic ChangesCanada
-
University of AlbertaAmerican Orthotic and Prosthetic AssociationSuspendedPain | Emergencies | Low Back Pain | Brace | Health Care ResourcesCanada
-
Clinique Romande de ReadaptationRecruitingHand Injuries and DisordersSwitzerland